44. Comparison between thallium-201 and Tc-99m mibi uptake in patients with brain tumors

D. Prosperi, M. Ricci, P. Pantano, A. Pierallini, M. Tuccimei, L. Bozzao

Research output: Contribution to journalArticle

Abstract

SPET with thallium-201 ( 201T1) is used in the assessment of brain tumors because the amount of 201T1 accumulated by the tumor cells is proportional to the degree of tumor malignancy, thus making it possible to differentiate high-grade from low-grade gliomas or recurrence from radiation necrosis. Tc 99m sestamibi has been more recently used to study brain tumors. It offers the advantages of Tc 99m labeled molecules including daily availability, good image contrast, low cost and short biological half-life. We studied 20 patients (9 m and 11 f, mean age: 51.3 ± 18 yrs) with histologically proven supratentorial brain tumors (low grade glioma = 4; high grade glioma = 7; radiation necrosis = 2; lymphoma = 1; meningioma = 3; metastasis = 2; histiocytosis = 1) with both the radiotracers (3 mCi of 201Tl and 20 mCi of Tc 99m sestamibi) in the same SPET session (Tomomatic 564, Medimatic; Denmark). All patients underwent MRI or CT scan shortly before the SPET study. The 201Tl and Tc 99m sestamibi uptake were calculated as the ratio between the average counts in a region of interest (ROI) of the tumor and the average counts in a symmetrical ROI in the unaffected hemisphere ( 201Tl and Tc 99m sestamibi indices). The tumor ROI was chosen on the slice showing the maximal tracer uptake. This ROI included all the tissue with tracer uptake higher than 50% of the maximum activity. The Tc 99m sestamibi index was significantly higher than the 201Tl index (2.8 ± 1.3 vs 2.3 ± .86, P =.02 t-paired test). A significant correlation was observed between 201Tl Index and Tc 99m sestamibi indices (y = 1.109x + .244; r = .736, p <.0002). These findings indicate that Tc 99m sestamibi has biological properties in brain tumors similar to those of 201Tl. Its practical advantages encourage a wider clinical application in the study of cerebral neoplasms.

Original languageEnglish
Pages (from-to)253-254
Number of pages2
JournalItalian Journal of Neurological Sciences
Volume18
Issue number4
Publication statusPublished - 1997

Fingerprint

Thallium
Brain Neoplasms
Glioma
Neoplasms
Necrosis
Supratentorial Neoplasms
Histiocytosis
Radiation
Meningioma
Denmark
Half-Life
Lymphoma
Neoplasm Metastasis
Costs and Cost Analysis
Recurrence

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

44. Comparison between thallium-201 and Tc-99m mibi uptake in patients with brain tumors. / Prosperi, D.; Ricci, M.; Pantano, P.; Pierallini, A.; Tuccimei, M.; Bozzao, L.

In: Italian Journal of Neurological Sciences, Vol. 18, No. 4, 1997, p. 253-254.

Research output: Contribution to journalArticle

@article{340e50b70d1e47fca9da93938fb34889,
title = "44. Comparison between thallium-201 and Tc-99m mibi uptake in patients with brain tumors",
abstract = "SPET with thallium-201 ( 201T1) is used in the assessment of brain tumors because the amount of 201T1 accumulated by the tumor cells is proportional to the degree of tumor malignancy, thus making it possible to differentiate high-grade from low-grade gliomas or recurrence from radiation necrosis. Tc 99m sestamibi has been more recently used to study brain tumors. It offers the advantages of Tc 99m labeled molecules including daily availability, good image contrast, low cost and short biological half-life. We studied 20 patients (9 m and 11 f, mean age: 51.3 ± 18 yrs) with histologically proven supratentorial brain tumors (low grade glioma = 4; high grade glioma = 7; radiation necrosis = 2; lymphoma = 1; meningioma = 3; metastasis = 2; histiocytosis = 1) with both the radiotracers (3 mCi of 201Tl and 20 mCi of Tc 99m sestamibi) in the same SPET session (Tomomatic 564, Medimatic; Denmark). All patients underwent MRI or CT scan shortly before the SPET study. The 201Tl and Tc 99m sestamibi uptake were calculated as the ratio between the average counts in a region of interest (ROI) of the tumor and the average counts in a symmetrical ROI in the unaffected hemisphere ( 201Tl and Tc 99m sestamibi indices). The tumor ROI was chosen on the slice showing the maximal tracer uptake. This ROI included all the tissue with tracer uptake higher than 50{\%} of the maximum activity. The Tc 99m sestamibi index was significantly higher than the 201Tl index (2.8 ± 1.3 vs 2.3 ± .86, P =.02 t-paired test). A significant correlation was observed between 201Tl Index and Tc 99m sestamibi indices (y = 1.109x + .244; r = .736, p <.0002). These findings indicate that Tc 99m sestamibi has biological properties in brain tumors similar to those of 201Tl. Its practical advantages encourage a wider clinical application in the study of cerebral neoplasms.",
author = "D. Prosperi and M. Ricci and P. Pantano and A. Pierallini and M. Tuccimei and L. Bozzao",
year = "1997",
language = "English",
volume = "18",
pages = "253--254",
journal = "Italian Journal of Neurological Sciences",
issn = "0392-0461",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - 44. Comparison between thallium-201 and Tc-99m mibi uptake in patients with brain tumors

AU - Prosperi, D.

AU - Ricci, M.

AU - Pantano, P.

AU - Pierallini, A.

AU - Tuccimei, M.

AU - Bozzao, L.

PY - 1997

Y1 - 1997

N2 - SPET with thallium-201 ( 201T1) is used in the assessment of brain tumors because the amount of 201T1 accumulated by the tumor cells is proportional to the degree of tumor malignancy, thus making it possible to differentiate high-grade from low-grade gliomas or recurrence from radiation necrosis. Tc 99m sestamibi has been more recently used to study brain tumors. It offers the advantages of Tc 99m labeled molecules including daily availability, good image contrast, low cost and short biological half-life. We studied 20 patients (9 m and 11 f, mean age: 51.3 ± 18 yrs) with histologically proven supratentorial brain tumors (low grade glioma = 4; high grade glioma = 7; radiation necrosis = 2; lymphoma = 1; meningioma = 3; metastasis = 2; histiocytosis = 1) with both the radiotracers (3 mCi of 201Tl and 20 mCi of Tc 99m sestamibi) in the same SPET session (Tomomatic 564, Medimatic; Denmark). All patients underwent MRI or CT scan shortly before the SPET study. The 201Tl and Tc 99m sestamibi uptake were calculated as the ratio between the average counts in a region of interest (ROI) of the tumor and the average counts in a symmetrical ROI in the unaffected hemisphere ( 201Tl and Tc 99m sestamibi indices). The tumor ROI was chosen on the slice showing the maximal tracer uptake. This ROI included all the tissue with tracer uptake higher than 50% of the maximum activity. The Tc 99m sestamibi index was significantly higher than the 201Tl index (2.8 ± 1.3 vs 2.3 ± .86, P =.02 t-paired test). A significant correlation was observed between 201Tl Index and Tc 99m sestamibi indices (y = 1.109x + .244; r = .736, p <.0002). These findings indicate that Tc 99m sestamibi has biological properties in brain tumors similar to those of 201Tl. Its practical advantages encourage a wider clinical application in the study of cerebral neoplasms.

AB - SPET with thallium-201 ( 201T1) is used in the assessment of brain tumors because the amount of 201T1 accumulated by the tumor cells is proportional to the degree of tumor malignancy, thus making it possible to differentiate high-grade from low-grade gliomas or recurrence from radiation necrosis. Tc 99m sestamibi has been more recently used to study brain tumors. It offers the advantages of Tc 99m labeled molecules including daily availability, good image contrast, low cost and short biological half-life. We studied 20 patients (9 m and 11 f, mean age: 51.3 ± 18 yrs) with histologically proven supratentorial brain tumors (low grade glioma = 4; high grade glioma = 7; radiation necrosis = 2; lymphoma = 1; meningioma = 3; metastasis = 2; histiocytosis = 1) with both the radiotracers (3 mCi of 201Tl and 20 mCi of Tc 99m sestamibi) in the same SPET session (Tomomatic 564, Medimatic; Denmark). All patients underwent MRI or CT scan shortly before the SPET study. The 201Tl and Tc 99m sestamibi uptake were calculated as the ratio between the average counts in a region of interest (ROI) of the tumor and the average counts in a symmetrical ROI in the unaffected hemisphere ( 201Tl and Tc 99m sestamibi indices). The tumor ROI was chosen on the slice showing the maximal tracer uptake. This ROI included all the tissue with tracer uptake higher than 50% of the maximum activity. The Tc 99m sestamibi index was significantly higher than the 201Tl index (2.8 ± 1.3 vs 2.3 ± .86, P =.02 t-paired test). A significant correlation was observed between 201Tl Index and Tc 99m sestamibi indices (y = 1.109x + .244; r = .736, p <.0002). These findings indicate that Tc 99m sestamibi has biological properties in brain tumors similar to those of 201Tl. Its practical advantages encourage a wider clinical application in the study of cerebral neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=33746328107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746328107&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33746328107

VL - 18

SP - 253

EP - 254

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

SN - 0392-0461

IS - 4

ER -